Amazing work, wondering if genome-wide antigen screens like TScan would reveal any new targets!
February 10, 2026 at 8:54 PM
Amazing work, wondering if genome-wide antigen screens like TScan would reveal any new targets!
#trading #stocks #invest
See stockquakes.com
Premarket - Dec 26, 2024
UP
↑ MGIH Millennium Group
↑ ADD Color Star Tech
↑ AIRE Realpha Tech
↑ TCRX Tscan
↑ SOBR Sobr Safe
DOWN
↓ LKCO Luokung Tech
↓ CLSK Cleanspark
↓ BBD Bank Bradesco
↓ VALE Vale S.A.
↓ NVDA Nvidia
See stockquakes.com
Premarket - Dec 26, 2024
UP
↑ MGIH Millennium Group
↑ ADD Color Star Tech
↑ AIRE Realpha Tech
↑ TCRX Tscan
↑ SOBR Sobr Safe
DOWN
↓ LKCO Luokung Tech
↓ CLSK Cleanspark
↓ BBD Bank Bradesco
↓ VALE Vale S.A.
↓ NVDA Nvidia
StockQuakes - AI Stock Analysis
Using AI to find stock market opportunities.
stockquakes.com
December 26, 2024 at 1:41 PM
#trading #stocks #invest
See stockquakes.com
Premarket - Dec 26, 2024
UP
↑ MGIH Millennium Group
↑ ADD Color Star Tech
↑ AIRE Realpha Tech
↑ TCRX Tscan
↑ SOBR Sobr Safe
DOWN
↓ LKCO Luokung Tech
↓ CLSK Cleanspark
↓ BBD Bank Bradesco
↓ VALE Vale S.A.
↓ NVDA Nvidia
See stockquakes.com
Premarket - Dec 26, 2024
UP
↑ MGIH Millennium Group
↑ ADD Color Star Tech
↑ AIRE Realpha Tech
↑ TCRX Tscan
↑ SOBR Sobr Safe
DOWN
↓ LKCO Luokung Tech
↓ CLSK Cleanspark
↓ BBD Bank Bradesco
↓ VALE Vale S.A.
↓ NVDA Nvidia
That's because the thick bastard is too lazy to understand how medecine works.
You screen higher risk groups first to reduce risk / improve their treatment outcomes
Has he been called in for his thick-as-pigshit scan yet? He's got to be high on the list. He doesn't have a CATscan he has a C**Tscan
You screen higher risk groups first to reduce risk / improve their treatment outcomes
Has he been called in for his thick-as-pigshit scan yet? He's got to be high on the list. He doesn't have a CATscan he has a C**Tscan
June 4, 2026 at 10:13 AM
That's because the thick bastard is too lazy to understand how medecine works.
You screen higher risk groups first to reduce risk / improve their treatment outcomes
Has he been called in for his thick-as-pigshit scan yet? He's got to be high on the list. He doesn't have a CATscan he has a C**Tscan
You screen higher risk groups first to reduce risk / improve their treatment outcomes
Has he been called in for his thick-as-pigshit scan yet? He's got to be high on the list. He doesn't have a CATscan he has a C**Tscan
BREAKING NEWS: ( NASDAQ: #TCRX ) TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
#StockMarket #News
#StockMarket #News
October 4, 2024 at 7:10 PM
Hangtao Zhang, Zhe Li, Kairui Zhang: TSCAN: Context-Aware Uplift Modeling via Two-Stage Training for Online Merchant Business Diagnosis https://arxiv.org/abs/2504.18881 https://arxiv.org/pdf/2504.18881 https://arxiv.org/html/2504.18881
April 29, 2025 at 6:04 AM
Hangtao Zhang, Zhe Li, Kairui Zhang: TSCAN: Context-Aware Uplift Modeling via Two-Stage Training for Online Merchant Business Diagnosis https://arxiv.org/abs/2504.18881 https://arxiv.org/pdf/2504.18881 https://arxiv.org/html/2504.18881
Just In: ( NASDAQ: #TCRX ) TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA(TM) Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
#StockMarket #News
#StockMarket #News
November 5, 2024 at 4:10 PM
Biotech layoffs are continuing as companies cut early programs and concentrate on their strongest assets. The industry is facing a harsh reality: promising science still needs enormous amounts of capital to reach patients
Layoff Tracker: TScan axes 75% of workforce, prioritizes solid tumor program
Follow along as BioSpace tracks job cuts and restructuring initiatives.
www.biospace.com
September 8, 2026 at 3:18 AM
Biotech layoffs are continuing as companies cut early programs and concentrate on their strongest assets. The industry is facing a harsh reality: promising science still needs enormous amounts of capital to reach patients
Signal or noise? > Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s
pipeline strategy >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #healthcare #pharma #competitivemarketing
pipeline strategy >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #healthcare #pharma #competitivemarketing
Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s
pipeline strategy
TScan has told Fierce that its pipeline strategy remains unchanged despite Amgen walking away from a Crohn’s disease collaboration that had the potential for a windfall of half a billion dollars.
dlvr.it
August 20, 2026 at 10:55 AM
Signal or noise? > Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s
pipeline strategy >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #healthcare #pharma #competitivemarketing
pipeline strategy >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #healthcare #pharma #competitivemarketing
TScan Therapeutics, Inc. (0001783328) (Filer) (cik: 0001783328) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1783328/000119312526388631/0001193125-26-388631-index.htm
September 11, 2026 at 2:00 PM
TScan Therapeutics, Inc. (0001783328) (Filer) (cik: 0001783328) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1783328/000119312526388631/0001193125-26-388631-index.htm
TScan Therapeutics, Inc. (0001783328) (Filer) (cik: 0001783328) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1783328/000119312526388631/0001193125-26-388631-index.htm
September 11, 2026 at 12:16 PM
TScan Therapeutics, Inc. (0001783328) (Filer) (cik: 0001783328) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1783328/000119312526388631/0001193125-26-388631-index.htm
🚨 $TCRX
On September 8, 2026, the Compensation Committee of the Board of Directors of TScan Therapeutics, Inc. approved a retention program designed to retain the employees required to support the Company, including a key employee retention program that provides for cash awards and the potential ...
On September 8, 2026, the Compensation Committee of the Board of Directors of TScan Therapeutics, Inc. approved a retention program designed to retain the employees required to support the Company, including a key employee retention program that provides for cash awards and the potential ...
SEC Filing: TCRX
Click to view the official SEC document.
www.sec.gov
September 11, 2026 at 12:01 PM
🚨 $TCRX
On September 8, 2026, the Compensation Committee of the Board of Directors of TScan Therapeutics, Inc. approved a retention program designed to retain the employees required to support the Company, including a key employee retention program that provides for cash awards and the potential ...
On September 8, 2026, the Compensation Committee of the Board of Directors of TScan Therapeutics, Inc. approved a retention program designed to retain the employees required to support the Company, including a key employee retention program that provides for cash awards and the potential ...
TScan Therapeutics $TCRX: HC Wainwright & Co. downgraded from Buy to Neutral and lowered its price target from $7.00 to $1.00.
https://fundspec.ai/s/TCRX/analysts
Draw trendlines and run technical studies on pro grade charts.
https://fundspec.ai/s/TCRX/analysts
Draw trendlines and run technical studies on pro grade charts.
September 8, 2026 at 3:15 PM
TScan Therapeutics $TCRX: HC Wainwright & Co. downgraded from Buy to Neutral and lowered its price target from $7.00 to $1.00.
https://fundspec.ai/s/TCRX/analysts
Draw trendlines and run technical studies on pro grade charts.
https://fundspec.ai/s/TCRX/analysts
Draw trendlines and run technical studies on pro grade charts.
TScan is pausing its Phase 3 TSC-101 trial and cutting approximately 75% of its workforce in a major strategic reset.
Follow Us for More!
Disclaimer: This is NOT a financial advice
Follow Us for More!
Disclaimer: This is NOT a financial advice
September 8, 2026 at 7:13 AM
TScan is pausing its Phase 3 TSC-101 trial and cutting approximately 75% of its workforce in a major strategic reset.
Follow Us for More!
Disclaimer: This is NOT a financial advice
Follow Us for More!
Disclaimer: This is NOT a financial advice
Needham Downgrades TScan Therapeutics to Hold From Buy https://finwires.com/en/article/needham-downgrades-tscan-therapeutics-hold-buy-7205935
Needham Downgrades TScan Therapeutics to Hold From Buy
finwires.com
September 3, 2026 at 4:01 AM
Needham Downgrades TScan Therapeutics to Hold From Buy https://finwires.com/en/article/needham-downgrades-tscan-therapeutics-hold-buy-7205935
TScan is latest cell therapy developer to pivot into in vivo #$TCRX firstwordpharma.com/story/7941531
September 2, 2026 at 10:01 PM
TScan is latest cell therapy developer to pivot into in vivo #$TCRX firstwordpharma.com/story/7941531
TScan Therapeutics Cuts 75% of Workforce, Pivots to Solid Tumors: TScan Therapeutics is reorganizing to prioritize an in vivo solid tumor program, cutting roughly 75% of its workforce and pausing enrollment in its Phase 3 ALLOHA-2 trial due to limited capital. The… #MarketUpdates Follow Us for more
TScan Therapeutics Cuts 75% of Workforce, Pivots to Solid Tumors
TScan Therapeutics is reorganizing to prioritize an in vivo solid tumor program, cutting roughly 75% of its workforce and pausing enrollment in its Phase 3 ALLOHA-2 trial due to limited capital. The restructuring is expected to save $55 million through 2027 and extend the company's cash runway into the fourth quarter of 2027.
quantli.com
September 2, 2026 at 10:19 PM
TScan Therapeutics Cuts 75% of Workforce, Pivots to Solid Tumors: TScan Therapeutics is reorganizing to prioritize an in vivo solid tumor program, cutting roughly 75% of its workforce and pausing enrollment in its Phase 3 ALLOHA-2 trial due to limited capital. The… #MarketUpdates Follow Us for more
TScan Therapeutics, Inc. (0001783328) (Filer) (cik: 0001783328) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/0001193125-26-379343-index.htm
September 2, 2026 at 11:35 AM
TScan Therapeutics, Inc. (0001783328) (Filer) (cik: 0001783328) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/0001193125-26-379343-index.htm
#$TCRX is shifting to in vivo TCR-T for solid tumors, pausing Phase 3 enrollment in TSC-101 and cutting about 75% of staff. Cash is expected to last into Q4 2027. notreload.xyz/xy/tcrx-pivo...
TScan Pivots to In Vivo T-Cell Therapy, Cuts 75% of Staff
TScan is shifting to in vivo TCR-T for solid tumors, pausing Phase 3 enrollment in TSC-101 and cutting about 75% of staff. Cash is expected to last into Q4 2027.
notreload.xyz
September 2, 2026 at 1:40 PM
#$TCRX is shifting to in vivo TCR-T for solid tumors, pausing Phase 3 enrollment in TSC-101 and cutting about 75% of staff. Cash is expected to last into Q4 2027. notreload.xyz/xy/tcrx-pivo...